Tim H. Brümmendorf

15.5k citations

298 papers · 9.0k indexed · 4 hit papers · h-index 46

Impact in

Hematology top 0.1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 188
- Chronic Myeloid Leukemia Treatments 143
- Acute Myeloid Leukemia Research 56
Genetics 157
- Chronic Lymphocytic Leukemia Research 104
- Myeloproliferative Neoplasms: Diagnosis and Treatment 40

Co-authors: Jörge E. Cortes Carlo Gambacorti‐Passerini Peter M. Lansdorp Stefan Balabanov Hagop M. Kantarjian Dong‐Wook Kim Nathalie Rufer Fabian Beier
Journals: Blood (70 papers)Journal of Clinical Oncology (22 papers)Leukemia (15 papers)Annals of Hematology (12 papers)Leukemia Research (7 papers)
Partner nations: Germany United States Italy

In The Last Decade

Tim H. Brümmendorf

288 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial 2017 · 320 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Clinical Oncology
2014 Genome biology
2012 Journal of Clinical Oncology
1999 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Tim H. Brümmendorf

Since Specialization

Citations

This map shows the geographic impact of Tim H. Brümmendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim H. Brümmendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim H. Brümmendorf more than expected).

Fields of papers citing papers by Tim H. Brümmendorf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim H. Brümmendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim H. Brümmendorf. The network helps show where Tim H. Brümmendorf may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim H. Brümmendorf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim H. Brümmendorf Line = papers co-authored together Tim H. Brümmendorf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms Nature Communications ·Ruth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak, Elisabeth Tregel, M. Saenz, Tim H. Brümmendorf, Steffen Koschmieder, Martin Grießhammer, Ines Gütgemann, Conny K. Baldauf, T Fischer, Peter Brossart, Carl Christian Kolbe, Eicke Latz, Dominik Wolf‎, Lino L. Teichmann	2025	0
2	Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study Leukemia Research ·B. Douglas Smith, Tim H. Brümmendorf, Gail J. Roboz, Carlo Gambacorti‐Passerini, Aude Charbonnier, Andrea Viqueira, Eric Leip, Simon Purcell, Erinn Hoag Goldman, Francis J. Giles, Thomas Ernst, Andreas Hochhaus, Gianantonio Rosti	2024	1
3	Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial Leukemia ·Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín García‐Gutiérrez, Henrik Hjorth‐Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gérald Luscan, Andrea Viqueira, Francis J. Giles, Andreas Hochhaus	2024	2
4	Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Leukemia ·Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, R Körber, Kim Kricheldorf, Susanne Isfort, Hartmut Döhner, Tim H. Brümmendorf, Martin Grießhammer, Konstanze Döhner, Steffen Koschmieder	2023	5
5	Telomere biology disorders may manifest as common variable immunodeficiency (CVID) Clinical Immunology ·Benjamin Rolles, Andrés Caballero-Oteyza, Michele Proietti, Sigune Goldacker, Klaus Warnatz, Nadezhda Camacho-Ordóñez, Seraina Prader, Jana Pachlopnik Schmid, Margherita Vieri, Susanne Isfort, Robert Meyer, Martin Kirschner, Tim H. Brümmendorf, Fabian Beier, Bodo Grimbacher	2023	3
6	XBP1 promotes NRAS^G12D pre‐B acute lymphoblastic leukaemia through IL‐7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS Journal of Cellular and Molecular Medicine ·Azam Salimi, Mirle Schemionek, Michael Huber, Margherita Vieri, John B. Patterson, Julia Alten, Tim H. Brümmendorf, Behzad Kharabi Masouleh, Iris Appelmann	2023	1
7	Transformative Materials for Interfacial Drug Delivery Advanced Healthcare Materials ·Prachi Desai, Anshuman Dasgupta, Alexandros Marios Sofias, Quim Peña, Robert Göstl, Ioana Slabu, Ulrich Schwaneberg, Thomas Stiehl, Wolfgang Wagner, Stefan Jockenhövel, Julia Stingl, Rafael Kramann, Christian Trautwein, Tim H. Brümmendorf, Fabian Kießling, Andreas Herrmann, Twan Lammers	2023	8
8	Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study Leukemia ·Gianantonio Rosti, Tim H. Brümmendorf, Bjørn Tore Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo Gambacorti‐Passerini, Thomas Ernst, Huadong Zhao, Luke Kuttschreuter, Simon Purcell, Francis J. Giles, Andreas Hochhaus	2023	3
9	ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia Leukemia ·Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saußele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst	2022	25
10	Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1) SHILAP Revista de lepidopterología ·Patrick P Hess, Mónica S. Ventura Ferreira, Benjamin Rolles, Martin Kirschner, Florian Holtbernd, Mareike Tometten, Tim H. Brümmendorf, Fabian Beier	2022	2
11	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial Leukemia ·Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, (unknown)	2022	79
12	Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) ·Natàlia Estrada, Blanca Xicoy, Fabian Beier, Olga García, Cristián Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora	2021	1
13	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation Blood ·Steffen Boettcher, C. Matthias Wilk, Jochen Singer, Fabian Beier, Elodie Burcklen, Christian Beisel, Mónica S. Ventura Ferreira, Elise Gourri, Christoph Gassner, Beat M. Frey, Urs Schanz, Radek C. Skoda, Benjamin L. Ebert, Tim H. Brümmendorf, Niko Beerenwinkel, Markus G. Manz	2020	50
14	Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita International Journal of Molecular Sciences ·Margherita Vieri, Martin Kirschner, Mareike Tometten, Anne Abels, Benjamin Rolles, Susanne Isfort, Jens Panse, Tim H. Brümmendorf, Fabian Beier	2020	18
15	Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms Leukemia ·Julian Baumeister, Nicolas Chatain, Annika Hubrich, Tiago Maié, Ivan G. Costa, Bernd Denecke, Lijuan Han, Caroline Küstermann, Stephanie Sontag, Kristin Seré, Klaus Strathmann, Martin Zenke, Andreas Schuppert, Tim H. Brümmendorf, Kamil R. Kranc, Steffen Koschmieder, Deniz Gezer	2019	41
16	Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature Clinical Case Reports ·Eva Jennes, Dorothee Guggenberger, Rainer B. Zotz, Lora M.A. Thompson, Tim H. Brümmendorf, Steffen Koschmieder, Edgar Jost	2017	4
17	Case report: a patient with acute myeloid leukemia and dyskeratosis congenita undergoing allogeneic stem cell transplantation: Implications for treatment RWTH Publications (RWTH Aachen) ·Anne‐Sophie Bouillon, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tim H. Brümmendorf, (unknown), (unknown), (unknown)	2016	0
18	JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms Cancer Research ·Kathrin Schönberg, Janna Rudolph, Maria Vonnahme, Sowmya Parampalli Yajnanarayana, Isabelle Cornez, Maryam Hejazi, Angela R. Manser, Markus Uhrberg, Walter Verbeek, Steffen Koschmieder, Tim H. Brümmendorf, Peter Brossart, Annkristin Heine, Dominik Wolf‎	2015	123
19	Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer Clinical Cancer Research ·Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fisch, Tim H. Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, Thorsten Schlomm	2010	110
20	Telomere Length Dynamics in Normal and Malignant Hematopoiesis Tim H. Brümmendorf, Peter M. Lansdorp, Nathalie Rufer	2000	2

About Tim H. Brümmendorf

Tim H. Brümmendorf is a scholar working on Hematology, Genetics, Rheumatology, Physiology and Oncology, having authored 298 papers that have together received 9.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (143 papers), Chronic Lymphocytic Leukemia Research (104 papers), Telomeres, Telomerase, and Senescence (59 papers), Acute Myeloid Leukemia Research (56 papers), Eosinophilic Disorders and Syndromes (54 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (40 papers), Acute Lymphoblastic Leukemia research (31 papers) and Cytomegalovirus and herpesvirus research (14 papers). The work is most often cited by research in Hematology (4.3k citations), Genetics (3.4k citations), Aging (278 citations), Rheumatology (1.7k citations) and Physiology (1.7k citations). Tim H. Brümmendorf has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Jörge E. Cortes, Carlo Gambacorti‐Passerini, Peter M. Lansdorp, Stefan Balabanov, Hagop M. Kantarjian, Dong‐Wook Kim, Nathalie Rufer, Fabian Beier, Eric Leip and H. Jean Khoury. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Annals of Hematology and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact